



Drug Discovery for Tropical Diseases

David Balnk*

Department of Pharmacology, University of South Carolina, USA

Abstract

Tropical diseases pose significant challenges to global public health, particularly in regions with limited resources and inadequate healthcare infrastructure. The development of effective drugs against these diseases is crucial for mitigating their impact and improving the well-being of affected populations. Drug discovery efforts for tropical diseases have seen notable progress in recent years, driven by advances in scientific understanding, technological innovation, and collaborative research initiatives. Target-based drug discovery approaches, focusing on identifying specific molecular targets within pathogens, have gained traction, leading to the discovery of novel drug candidates with potential efficacy against diseases such as malaria, dengue fever, leishmaniasis, and Chagas disease. This abstract provides an overview of recent advancements in drug discovery for tropical diseases, highlighting key strategies, challenges, and opportunities in this field.

***Corresponding author:** David Balnk, Department of Pharmacology, University of South Carolina, USA, E-mail: davidblank@usc.ac.org

Received: 04-Mar-2024, Manuscript No: wjpt-24-128182, **Editor assigned:** 05-Mar-2024, PreQC No: wjpt-24-128182(PQ), **Reviewed:** 25-Mar-2024, QC No: wjpt-24-128182, **Revised:** 26-Mar-2024, Manuscript No: wjpt-24-128182(R), **Published:** 31-Mar-2024, DOI: 10.4172/wjpt.1000238

Citation: Balnk D (2024) Drug Discovery for Tropical Diseases. World J Pharmacol Toxicol 7: 238.

Copyright: © 2024 Balnk D. This is an open-access article distributed under the

a . C a a a a c c a x b ac a a ca a a , a c ca a .D ca , ca c a , a a ba , a c a c a a a ac c .O c c a c c ab a b aca a, , , - a a , a a c c a a c , , a acc c a .

Drug resistance

a a c a a - a a ca c a a ca a ca a a cac [9].

Limited nancial incentives

a c ca ab c ca a ac ca c a a c a .

Regulatory barriers

Ob a a a a , a c a a c c - , ca b c a a a a c c c ca a . A c a a a a a ac c a . B a a a c c c a c , a a a b aca a, , , a - a a , ba c ca acc a a , a , c , a acc b ca a , a a a -b [10].

Conclusion

I c c , a a c c a a a a b ac a a b a a a a c ab a ca a b ca . c c c c a , c ca , a c ab a a ,

c a .D ca , ca c a , a a ba , a c a c a a a ac c .O c c a c c ab a b aca a, , , - a a , a a c c a a c , , a acc c a .

References

1. Lammerhofer M, Weckwerth W (2013) *Metabolomics in practice: successful strategies to generate and analyze metabolic data*. Weinheim: Wiley-VCH Verlag.
2. Haycock JW (2011) 3D cell culture: a review of current approaches and techniques. *Methods Mol Biol.* 695:1-15.
3. Fatehullah A, Tan SH, Barker N (2016) Organoids as an in vitro model of human development and disease. *Nat Cell Biol.* 18: 246-254.
4. Jeong ES, Kim G, Shin HJ (2015) Increased serum bile acid concentration following low-dose chronic administration of thioacetamide in rats, as evidenced by metabolomic analysis. *Toxicol Appl Pharmacol.* 288: 213-222.
5. Mattes W, Davis K, Fabian E (2014) Detection of hepatotoxicity potential with metabolite profiling (metabolomics) of rat plasma. *Toxicol Lett.* 230: 467-478.
6. Weiler S, Merz M, Kullak-Ublick GA (2015) Drug-induced liver injury: the dawn of biomarkers? *F1000Prime Rep.* 7: 34.
7. Zaitseva K, Hayashi Y, Kusano M (2016) Application of metabolomics to toxicology of drugs of abuse: a mini review. *Journal of Analytical Applied M P*